Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide. It has also been demonstrated that over the last ten years the incidence of CRC among younger people below the age of 50 is also increasing. Screening for colorectal cancer is of utmost importance; the rationale behind screening is to target the malignancy and reduce the incidence and mortality of the disease. Diagnostic methods to screen for incidence or relapse are therefore a requisite to detect cancer as early as possible. Scientific findings demonstrate that many deaths are due to lack of screening and therefore early identification will lead to greater survivability. In colorectal cancer, diagnostic tests include liquid biopsy biomarkers. Since the discovery of microRNAs (miRNAs), many studies have demonstrated the relationship between miRNAs and the various sub-types of CRC. Several miRNAs have been identified after analysing serum or plasma samples in patients, and such miRNAs were found to be significantly dysregulated. Such findings place the possibility of miRNAs to be at the epicentre of novel diagnostic techniques for CRC identification and sub-type stratification, including other characteristics associated with CRC development such as patient prognosis. The following review serves to underline the latest findings for miRNAs with such potential for routine diagnostic employment in CRC diagnostics and treatments.

Keywords

MicroRNA / miRNA / liquid biopsy / biomarkers / colorectal cancer / cancer

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[2] Wang YN,Chen WC.Novel circulating microRNAs expression profile in colon cancer: a pilot study.Eur J Med Res2017;22:51 PMCID:PMC5707919

[3] Chen B,Deng YN.Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis.Open Biol2019;9:180212 PMCID:PMC6367136

[4] Campos FGCM,Monteiro M,Cecconello I.Incidence of colorectal cancer in young patients.Rev Col Bras Cir2017;44:208-15

[5] Yang J.The association of diet, gut microbiota and colorectal cancer: what we eat may imply what we get.Protein Cell2018;9:474-87 PMCID:PMC5960467

[6] Bailey CE,You YN.Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010.JAMA Surg2015;150:17-22 PMCID:PMC4666003

[7] Campos FG,Martinez CA.Colorectal cancer risk in hamartomatous polyposis syndromes.World J Gastrointest Surg2015;7:25-32 PMCID:PMC4381153

[8] Schlussel AT,Seto-Donlon S.The evolution of colorectal cancer genetics-Part 1: from discovery to practice.J Gastrointest Oncol2014;5:326-35 PMCID:PMC4173047

[9] Simard J,Kircher S.Survivorship guidance for patients with colorectal cancer.Curr Treat Options Oncol2019;20:38

[10] Fleming M,Tatishchev SF.Colorectal carcinoma: pathologic aspects.J Gastrointest Oncol2012;3:153-73 PMCID:PMC3418538

[11] Dimitrakopoulou-Strauss A,Cheng C.Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.Clin Transl Imaging2017;5:183-97 PMCID:PMC5658474

[12] Tevlin R,Hyland JM,Winter DC.Primary colorectal lymphoma - a single centre experience.Surgeon2015;13:151-5

[13] Beaton C,Beynon J.The management of primary small bowel and colon lymphoma--a review.Int J Colorectal Dis2012;27:555-63

[14] Gay ND,Okada CY.Colorectal lymphoma: a review.Clin Colon Rectal Surg2018;31:309-16 PMCID:PMC6123013

[15] Wong MT.Primary colorectal lymphomas.Colorectal Dis2006;8:586-91

[16] Salyers WJ,Munoz JC,Tanev SS.Neuroendocrine tumors of the gastrointestinal tract: case reports and literature review.World J Gastrointest Oncol2014;6:301-10 PMCID:PMC4133797

[17] Degnan AJ,Kurtom W.Pediatric neuroendocrine carcinoid tumors: management, pathology, and imaging findings in a pediatric referral center.Pediatr Blood Cancer2017;64:e26477

[18] Busbait S,Tawfeeq Y,Al-buainain H.Turcot's syndrome presenting as an acute abdomen.J Pediatr Surg Case Rep2019;40:17-9

[19] Lebrun C,Jeannin S,Sobol H.Turcot syndrome confirmed with molecular analysis.Eur J Neurol2007;14:470-2

[20] Daniell J,Perera A.An exploration of genotype-phenotype link between Peutz-Jeghers syndrome and STK11: a review.Fam Cancer2018;17:421-7

[21] Tan H,Huang Y.Three novel mutations of STK11 gene in Chinese patients with Peutz-Jeghers syndrome.BMC Med Genet2016;17:77 PMCID:PMC5100203

[22] Chen HY,Li BR.Cancer risk in patients with Peutz-Jeghers syndrome: a retrospective cohort study of 336 cases.Tumour Biol2017;39:1010428317705131

[23] Qiu Y,Yin M.Clinical characteristics and genetic analysis of gene mutations in a Chinese pedigree with Peutz-Jeghers syndrome.Clin Case Rep2019;7:735-9 PMCID:PMC6452494

[24] Armelao F.Familial colorectal cancer: a review.World J Gastroenterol2014;20:9292-8 PMCID:PMC4110560

[25] Rosty C.The role of the surgical pathologist in the diagnosis of gastrointestinal polyposis syndromes.Adv Anat Pathol2018;25:1-13

[26] Jaoude JB,Rassy EE.The role of prophylactic gastrectomy in patients with juvenile polyposis syndrome.Clin Res Hepatol Gastroenterol2019;43:e42-3

[27] Sur D,Sur G,Dascal L.Colorectal cancer: evolution of screening strategies.Med Pharm Rep2019;92:21-4 PMCID:PMC6448494

[28] Wender RC,Fedewa SA,Smith RA.A blueprint for cancer screening and early detection: advancing screening's contribution to cancer control.CA Cancer J Clin2019;69:50-79

[29] Hadjipetrou A,Galanakis CG,Kastanakis S.Colorectal cancer, screening and primary care: a mini literature review.World J Gastroenterol2017;23:6049-58 PMCID:PMC5597496

[30] Li JN.Fecal occult blood test in colorectal cancer screening.J Dig Dis2019;20:62-4

[31] Kościelniak-Merak B,Zając A.Faecal occult blood point-of-care tests.J Gastrointest Cancer2018;49:402-5 PMCID:PMC6208834

[32] Berry E,Koch M,Argenbright K.Lower abnormal fecal immunochemical test cut-off values improve detection of colorectal cancer in system-level screens.Clin Gastroenterol Hepatol2020;18:647-53 PMCID:PMC7731666

[33] Dollinger MM,Fleig WE.Early Detection of colorectal cancer: a multi-center pre-clinical case cohort study for validation of a combined DNA stool test.Clin Lab2018;64:1719-30

[34] Vacante M,Basile F.Biomarkers in colorectal cancer: current clinical utility and future perspectives.World J Clin Cases2018;6:869-81 PMCID:PMC6288499

[35] Leung WC,Chan TT.Alternatives to colonoscopy for population-wide colorectal cancer screening.Hong Kong Med J2016;22:70-7

[36] El Zoghbi M, Cummings LC. New era of colorectal cancer screening.World J Gastrointest Endosc2016;8:252-8 PMCID:PMC4781905

[37] Kroijer R,Qvist N,Baatrup G.Colon capsule endoscopy for colonic surveillance.Colorectal Dis2019;21:532-7

[38] Milluzzo SM,Cesaro P.Colon capsule endoscopy and its effectiveness in the diagnosis and management of colorectal neoplastic lesions.Expert Rev Anticancer Ther2019;19:71-80

[39] Miller EA,Schoen RE,Church TR.Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial.Lancet Gastroenterol Hepatol2019;4:101-10 PMCID:PMC6335177

[40] Segev L,Church JM.Left-sided dominance of early-onset colorectal cancers: a rationale for screening flexible sigmoidoscopy in the young.Dis Colon Rectum2018;61:897-902

[41] Quero G,Hassan C.Colonoscopy quality assessment and accuracy: analysis of the influencing factors and surgical sequelae on 216 colonoscopies.Eur Rev Med Pharmacol Sci2019;23:2532-8

[42] Hernández G,Quintero E.Strategies to optimise the quality of bowel cleansing.Gastroenterol Hepatol2019;42:326-38

[43] Zhang Q,Wang J.Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients.Oncotarget2015;6:15095-110 PMCID:PMC4558138

[44] Nahacka Z,Peterka M.TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.Biochim Biophys Acta Mol Cell Res2018;1865:522-31

[45] Mehta RS,Song M.Association between plasma levels of macrophage inhibitory cytokine-1 before diagnosis of colorectal cancer and mortality.Gastroenterology2015;149:614-22 PMCID:PMC4550565

[46] Lam K,Linnekamp JF,Kandimalla R.DNA methylation based biomarkers in colorectal cancer: a systematic review.Biochim Biophys Acta2016;1866:106-20

[47] Graule J,Fischer E.CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.Clin Epigenetics2018;10:120 PMCID:PMC6158822

[48] Ren A,Tsoi H.Detection of miRNA as non-invasive biomarkers of colorectal cancer.Int J Mol Sci2015;16:2810-23 PMCID:PMC4346866

[49] Iwakawa HO.The functions of microRNAs: mRNA decay and translational repression.Trends Cell Biol2015;25:651-65

[50] Ruebel K,Stilling GA.MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression.Mod Pathol2010;23:367-75 PMCID:PMC2886953

[51] Mitsuhashi K,Kurihara H.Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy.Oncotarget2015;6:22114-25 PMCID:PMC4673150

[52] Li SC,Martijn C.Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors.Mod Pathol2013;26:685-96 PMCID:PMC3647117

[53] Fan R,Zheng S.microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.Clin Exp Med2015;15:137-44

[54] Cao CL,Kang SP,Kang SR.MiRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to imatinib via targeting B-cell lymphoma 2 (Bcl-2).Eur Rev Med Pharmacol Sci2016;20:3574-81

[55] Kim WK,Kim YK.MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.Clin Cancer Res2011;17:7584-94

[56] Wang Y,Kuang D.miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT.Cell Commun Signal2018;16:16 PMCID:PMC5902930

[57] Niinuma T,Kitajima H.Downregulation of miR-186 is associated with metastatic recurrence of gastrointestinal stromal tumors.Oncol Lett2017;14:5703-10 PMCID:PMC5661378

[58] Ihle MA,Kuenstlinger H.miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours.Mol Oncol2015;9:1421-33 PMCID:PMC5528808

[59] Yamamoto H,Fujita A.Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor.Mod Pathol2013;26:563-71

[60] Liu S,Liao G.MiR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor.Tumour Biol2014;35:9131-8

[61] Shi Y,Hu Q.PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.Lab Invest2016;96:652-60

[62] Lu HJ,Jin PY.MicroRNA-152 inhibits tumor cell growth while inducing apoptosis via the transcriptional repression of cathepsin L in gastrointestinal stromal tumor.Cancer Biomark2018;21:711-22

[63] Knudsen KN,Lindebjerg J,Holst R.microRNA-17 is the most up-regulated member of the miR-17-92 cluster during early colon cancer evolution.PLoS One2015;10:e0140503 PMCID:PMC4605595

[64] Hu J,Cai S.Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma.Eur J Med Res2015;20:95 PMCID:PMC4667483

[65] Wang JY,Wang XM.Comprehensive analysis of MicroRNA/MRNA signature in colon adenocarcinoma.Eur Rev Med Pharmacol Sci2017;21:2114-29

[66] Perilli L,Agostini M.Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression.Oncotarget2014;5:6611-9 PMCID:PMC4196150

[67] Aslam MI,West K,Jameson JS.MicroRNAs associated with initiation and progression of colonic polyp: a feasibility study.Int J Surg2015;13:272-9

[68] Nagy ZB,Kalmár A.Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens.Clin Epigenetics2017;9:22 PMCID:PMC5310023

[69] Sun CM.Overexpression of microRNA-21 in peripheral blood mononuclear cells of patients with B-cell non-Hodgkin's lymphoma is associated with disease stage and treatment outcome.Eur Rev Med Pharmacol Sci2015;19:3397-402

[70] Takei Y,Kisaka M.Determination of abnormally expressed microRNAs in bone marrow smears from patients with follicular lymphomas.Springerplus2014;3:288 PMCID:PMC4072855

[71] Yuan WX,Na WN,Yang X.Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients.Oncol Lett2016;11:423-32 PMCID:PMC4726930

[72] Cui Q,Cristino AS.Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma.Oncotarget2018;9:34644-57 PMCID:PMC6205167

[73] Bartolomé-Izquierdo N,Álvarez-Prado AF.miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma.Blood2017;129:2408-19 PMCID:PMC5437734

[74] Anvarnia A,Asadi M,Yousefi B.Dysregulated microRNAs in colorectal carcinogenesis: new insight to cell survival and apoptosis regulation.J Cell Physiol2019;234:21683-93

[75] To KK,Wu M.MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside.World J Gastroenterol2018;24:2949-73 PMCID:PMC6054943

[76] Ding J,Song J,Huang L.MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7.Acta Biochim Biophys Sin (Shanghai)2018;50:597-604

[77] Wu QB,Zhang N,Wang F.Role of microRNAs in the resistance of colorectal cancer to chemoradiotherapy.Mol Clin Oncol2018;8:523-7 PMCID:PMC5844042

[78] Subramanian S,Lee CH.MicroRNA expression signature of human sarcomas.Oncogene2008;27:2015-26

[79] Kelly L,Kim SY.NIH Pediatric and Wild-Type GIST ClinicPost-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST].PLoS One2013;8:e64102 PMCID:PMC3663836

[80] Akçakaya P,Åhlen J.microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.Br J Cancer2014;111:2091-102 PMCID:PMC4260040

[81] Khoury S.Circulating microRNAs: potential biomarkers for common malignancies.Biomark Med2015;9:131-51

[82] Treiber T,Meister G.Regulation of microRNA biogenesis and its crosstalk with other cellular pathways.Nat Rev Mol Cell Biol2019;20:5-20

[83] Carter JV,Yang D,Walker SP.Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis.Br J Cancer2017;116:762-74 PMCID:PMC5355921

[84] Germano G,Siravegna G.Parallel evaluation of circulating tumor DNA and circulating tumor cells in metastatic colorectal cancer.Clin Colorectal Cancer2018;17:80-3

[85] Liu HN,Wu H.Serum microRNA signatures and metabolomics have high diagnostic value in colorectal cancer using two novel methods.Cancer Sci2018;109:1185-94 PMCID:PMC5891204

[86] Liu HN,Tseng YJ.Serum microRNA signatures and metabolomics have high diagnostic value in gastric cancer.BMC Cancer2018;18:415 PMCID:PMC5899358

[87] Toiyama Y,Fleshman J,Goel A.MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: a systematic review.Biochim Biophys Acta Rev Cancer2018;1870:274-82 PMCID:PMC7286572

[88] Du B,Yang X.The expression and significance of microRNA in different stages of colorectal cancer.Medicine (Baltimore)2018;97:e9635 PMCID:PMC5805415

[89] Vychytilova-Faltejskova P,Sachlova M.Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer.Carcinogenesis2016;37:941-50

[90] Yang J,Fesler A.Expression analysis of microRNA as prognostic biomarkers in colorectal cancer.Oncotarget2017;8:52403-12 PMCID:PMC5581037

[91] Ogata-Kawata H,Kurioka D.Circulating exosomal microRNAs as biomarkers of colon cancer.PLoS One2014;9:e92921 PMCID:PMC3976275

[92] Jacob H,Storli KE,Dahl O.Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer.Oncotarget2017;8:87837-47 PMCID:PMC5675676

[93] Coebergh van den Braak RRJ, Sieuwerts AM, Lalmahomed ZS, et al; MATCH study group*. Confirmation of a metastasis-specific microRNA signature in primary colon cancer.Sci Rep2018;8:5242 PMCID:PMC5869672

[94] Jacob H,Storli KE,Dahl O.A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer.Sci Rep2018;8:6157 PMCID:PMC5906690

[95] Zhu M,Zhu D.A panel of microRNA signature in serum for colorectal cancer diagnosis.Oncotarget2017;8:17081-91 PMCID:PMC5370024

[96] Zhang H,Shan X.A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis.Gene2019;687:246-54

[97] Wikberg ML,Palmqvist R,Ljuslinder I.Plasma miRNA can detect colorectal cancer, but how early?.Cancer Med2018;7:1697-705 PMCID:PMC5943420

[98] Karimi N,Safaralizadeh R.Serum overexpression of miR-301a and miR-23a in patients with colorectal cancer.J Chin Med Assoc2019;82:215-20

[99] Liu X,Pan B.Circulating miR-1290 and miR-320d as novel diagnostic biomarkers of human colorectal cancer.J Cancer2019;10:43-50 PMCID:PMC6329864

[100] Yang Q,Huang J,Jin H.Serum miR-20a and miR-486 are potential biomarkers for discriminating colorectal neoplasia: a pilot study.J Cancer Res Ther2018;14:1572-7

[101] Chang PY,Chang YS.MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection.Oncotarget2016;7:10663-75 PMCID:PMC4891149

[102] Zhou X,Shan X.A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis.Oncotarget2017;8:6513-25 PMCID:PMC5351649

[103] Monzo M,Moreno I.Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer.Oncotarget2017;8:30859-69 PMCID:PMC5458173

[104] Montagnana M,Danese E.Plasma expression levels of circulating miR-21 are not useful for diagnosing and monitoring colorectal cancer.Clin Lab2016;62:967-70

[105] Micallef I.The mechanistic roles of ncRNAs in promoting and supporting chemoresistance of colorectal cancer.Noncoding RNA2021;7:24 PMCID:PMC8103280

[106] Sasaki M,Ishiguro M.The effectiveness of plasma miR-33a-5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy.Oncol Lett2021;21:489 PMCID:PMC8100963

[107] Li J,Zheng L.MicroRNA-490-3p inhibits migration and chemoresistance of colorectal cancer cells via targeting TNKS2.World J Surg Oncol2021;19:117 PMCID:PMC8045283

[108] Mou Y,Su M.MiR-1254 and MEGF6 regulates oxaliplatin resistance in human colorectal cancer cells.Am J Transl Res2021;13:183-96 PMCID:PMC7847511